Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Marin

Showing results (171-180 of 197) with videos related to

Pageof 20
Sort By:
Bone Marrow Transplantation|November 23, 2006
LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centreJ B Perz, C Giles, R Szydlo, et al.
Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society|January 11, 2021
The impact of different extracts of six Lamiaceae species on deleterious effects of oxidative stress assessed in acellular, prokaryotic and eukaryotic models <i>in vitro</i>Mariana M Oalđe, Stoimir M Kolarević, Jelena C Živković, et al.
Bone Marrow Transplantation|May 21, 2013
Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCTA J Innes, R Beattie, R Sergeant, et al.
Molecular Therapy Oncolytics|March 14, 2022
A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cellsCelia C Cubitt, Ethan McClain, Michelle Becker-Hapak, et al.
Leukemia|August 17, 2011
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinibD Marin, I H Gabriel, S Ahmad, et al.
Leukemia|July 21, 2017
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activityE Liu, Y Tong, G Dotti, et al.
Cell Reports|June 4, 2020
Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and CytotoxicityJulia A Wagner, Pamela Wong, Timothy Schappe, et al.
Blood|January 22, 2020
Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomasS A Srour, H Singh, J McCarty, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 27, 2015
Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell RecipientsA Abudayyeh, A Hamdi, H Lin, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Pageof 20

Showing results (171-180 of 197) with videos related to

Sort By:
Pageof 20
Bone Marrow Transplantation|November 23, 2006
LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centreJ B Perz, C Giles, R Szydlo, et al.
Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society|January 11, 2021
The impact of different extracts of six Lamiaceae species on deleterious effects of oxidative stress assessed in acellular, prokaryotic and eukaryotic models <i>in vitro</i>Mariana M Oalđe, Stoimir M Kolarević, Jelena C Živković, et al.
Bone Marrow Transplantation|May 21, 2013
Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCTA J Innes, R Beattie, R Sergeant, et al.
Molecular Therapy Oncolytics|March 14, 2022
A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cellsCelia C Cubitt, Ethan McClain, Michelle Becker-Hapak, et al.
Leukemia|August 17, 2011
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinibD Marin, I H Gabriel, S Ahmad, et al.
Leukemia|July 21, 2017
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activityE Liu, Y Tong, G Dotti, et al.
Cell Reports|June 4, 2020
Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and CytotoxicityJulia A Wagner, Pamela Wong, Timothy Schappe, et al.
Blood|January 22, 2020
Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomasS A Srour, H Singh, J McCarty, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 27, 2015
Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell RecipientsA Abudayyeh, A Hamdi, H Lin, et al.
Leukemia|June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyF J Giles, E Abruzzese, G Rosti, et al.
Pageof 20